What's breaking now, across thousands of outlets.
Side effects observed in testing have led Novartis to halt development of rap-cel in multiple indications and Bristol Myers to voluntarily pause its zola-cel program.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
(MedPage Today) -- Use of GLP-1 receptor agonists was associated with increased cumulative gallbladder and biliary events in youths, according to a retrospective analysis of TriNetX data.
Naegleria fowleri is commonly found in warm freshwater, and if it enters through the nose, can cause brain damage A North Carolina teenager has died after contracting a rare and often fatal…
(MedPage Today) -- Recent studies suggest that people with type 2 diabetes on GLP-1 receptor agonists were less likely to develop tuberculosis (TB) or be hospitalized or die from infections.
Kenya has secured a major breakthrough in cancer treatment after signing an agreement with US pharmaceutical giant Pfizer that will significantly reduce the cost of medicines used to treat several…
A new spatial transcriptomics framework compares tumor “floor plans." In a study of 262 solid tumors, the team identified recurring spatial groups that may connect spatial structure, biological…
Kenya is moving to bring traditional medicine into the formal healthcare system as the government steps up efforts to strengthen research, regulation and local production of medicines.
